Form 4: Fulgent Genetics CFO Sells Shares for Tax Obligations

Fulgent Genetics' CFO, Paul Kim, disposed of 2,743 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Paul Kim, Chief Financial Officer and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a transaction involving the company's common stock.
• On October 26, 2025, Mr. Kim disposed of 2,743 shares of common stock.
• The shares were valued at $23.74 per share for the transaction.
• This disposition was made to satisfy tax withholding obligations arising from the vesting of certain restricted stock units.
• These restricted stock units were assumed as part of the Agreement and Plan of Merger dated November 7, 2022.
• Following this transaction, Mr. Kim beneficially owns 334,118 shares of Fulgent Genetics common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were disposed, it was a non-discretionary sale for tax purposes following the vesting of equity awards, which is a positive event for the executive. It does not indicate a negative outlook on the company.

Positives

• The underlying event, the vesting of restricted stock units, represents a positive compensation event for the executive.

Negatives

• The disposition of shares was a non-discretionary sale to cover tax liabilities, not a voluntary sale indicating a lack of confidence in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction is a routine insider filing (Form 4) common for executives receiving equity compensation. It reflects the standard practice of withholding shares to cover tax liabilities upon the vesting of restricted stock units, a common form of executive compensation in the industry.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or executive confidence.
• Employees: No direct impact on general employees.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the CFO to cover tax obligations arising from the vesting of restricted stock units. Such transactions are common and do not typically reflect a change in the executive's confidence in the company or its future prospects. Therefore, it provides no new fundamental information that would warrant a change in investment recommendation. Investors should hold their position based on broader company performance and market conditions.

Keywords

Fulgent Genetics, FLGT, Paul Kim, CFO, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units